BI-224436
| CAS No. | 1155419-89-8 | Cat. No. | BCP26024 |
| Name | BI-224436 | ||
| Synonyms | BI 224436; BI224436; | ||
| Formula | C27H26N2O4 | M. Wt | 442.51 |
| Description | BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site. | ||
| Pathways | Microbiology/Virology | ||
| Targets | HIV | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.